EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Lipid‐Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double‐Blind, Parallel, Multicenter, Phase 3 Clinical Trial

You-Jeong Ki, Weon Kim, Ki Hong Lee, Sang-Jin Han, Yong-Hyun Kim, Joon-Hyung Doh, Tae Nyun Kim, Choon Hee Chung, Do Young Kim, Jin-Man Cho, Hyuck-Jun Yoon, In-Kyung Jeong und 10 weitere

Clinical Cardiology · 2025

DOI: 10.1002/clc.70138 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Cardiology, 2025. Verfasst von You-Jeong Ki und 21 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Center, Department of Internal Medicine, Uijeongbu Eulji Medical Center, Uijeongbu, Republic of Korea. Hauptthemen laut MEDLINE: Anticholesteremic Agents, Atorvastatin, Cholesterol, LDL, Dyslipidemias. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This study was funded by the Daewon Pharmaceutical Co. Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to compare the lipid‐lowering effect and safety of low‐intensity atorvastatin (5 mg) plus ezetimibe (10 mg) combination therapy (A5E10) with monotherapy regimens–atorvastatin 5 mg [A5], ezetimibe 10 mg [E10], and atorvastatin 10 mg [A10])–in dyslipidemia patients.

Methods

A randomized, double‐blind, placebo‐controlled trial involving 252 dyslipidemia patients was conducted at 25 centers in South Korea (NCT05970679). Participants aged ≥ 19 years were randomized into four groups: A5E10, A5, E10, and A10. The primary endpoint was the percentage change in low‐density lipoprotein cholesterol (LDL‐C) levels from baseline to 8 weeks. Secondary endpoints included changes in other lipid parameters, lipid ratios, LDL‐C goal achievement rates and safety assessments.

Results

The mean age of the patients was 63 years, and 51.2% were male. The A5E10 group showed significantly greater LDL‐C reduction (47.6%) compared with A5 (33.4%), E10 (19.4%), and A10 (40.1%) at 8 weeks ( p < 0.0001). A5E10 also significantly reduced triglyceride, non‐high‐density lipoprotein cholesterol, and apolipoprotein B levels. In addition, a significant reduction in LDL‐C levels was observed over the 4 weeks, with a 46.7% reduction in LDL‐C levels after 4 weeks of A5E10 administration. No severe adverse events were observed in the A5E10 group.

Conclusion

The combination of low‐intensity atorvastatin and ezetimibe was more effective than moderate‐intensity atorvastatin monotherapy in lowering LDL‐C levels and improving other lipid parameters. It was well‐tolerated and demonstrated rapid benefits within a month, offering a promising alternative for patients with low to moderate cardiovascular risk who do not achieve adequate control with statin monotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anticholesteremic AgentsAtorvastatinCholesterol, LDLDyslipidemiasEzetimibeHypercholesterolemiaLipidsAdultAgedFemaleHumansMaleMiddle AgedBiomarkersDouble-Blind MethodDrug Therapy, CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsRepublic of KoreaTime FactorsTreatment Outcome

Stichwörter der Autor:innen

atorvastatincholesterolezetimibestatin

Substanzen

Anticholesteremic AgentsAtorvastatinBiomarkersCholesterol, LDLEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsLipids

Autor:innen und Institutionen

  • Cardiovascular Center, Department of Internal Medicine, Uijeongbu Eulji Medical Center, Uijeongbu, Republic of Korea.
  • Cardiovascular Division, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, Republic of Korea.
  • Cardiovascular Division, Department of Internal Medicine, Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea.
  • Division of Cardiology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Republic of Korea.
  • Department of Endocrinology, Bundang Jesaeng Hospital, Bundang-gu, Gyeonggido, Republic of Korea.
  • Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.

Förderung

  • This study was funded by the Daewon Pharmaceutical Co. Ltd.

Zitieren

APA

Ki, Y. J., Kim, W., Lee, K. H., Han, S. J., Kim, Y. H., Doh, J. H., Kim, T. N., Chung, C. H., Kim, D. Y., Cho, J. M., Yoon, H. J., Jeong, I. K., Park, S., Song, K. H., Yu, C. W., Cho, D. K., Choi, S. H., Oh, S. J., Shin, S., …, & Kim, H. S. (2025). Lipid‐Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double‐Blind, Parallel, Multicenter, Phase 3 Clinical Trial. Clinical Cardiology. https://doi.org/10.1002/clc.70138

Vancouver

Ki YJ, Kim W, Lee KH, Han SJ, Kim YH, Doh JH, et al. Lipid‐Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double‐Blind, Parallel, Multicenter, Phase 3 Clinical Trial. Clinical Cardiology. 2025. doi:10.1002/clc.70138

BibTeX
@article{Ki2025,
  author = {Ki, You-Jeong and Kim, Weon and Lee, Ki Hong and Han, Sang-Jin and Kim, Yong-Hyun and Doh, Joon-Hyung and Kim, Tae Nyun and Chung, Choon Hee and Kim, Do Young and Cho, Jin-Man and Yoon, Hyuck-Jun and Jeong, In-Kyung and Park, Sungha and Song, Kee-Ho and Yu, Cheol Woong and Cho, Deok-Kyu and Choi, Sung Hee and Oh, Seung-Jin and Shin, Sanghoon and Jeong, Hyeonju and Park, Yongwhi and Kim, Hyo-Soo},
  title = {Lipid‐Lowering Effect and Safety of Ezetimibe and Atorvastatin 5 mg in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia: A Randomized, Double‐Blind, Parallel, Multicenter, Phase 3 Clinical Trial},
  journal = {Clinical Cardiology},
  year = {2025},
  doi = {10.1002/clc.70138}
}
Kostenlos starten →